Home| Professor of Neuroimmunology |
Publications since 2001
• Baker D , Pryce G, Croxford JL, Brown P, A.Makryiannis, JW Pertwee R, Layward L and Di Marzo V. (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15:300-302
• Croxford JL, Feldmann M, Chernajovsky Y and Baker D . (2001) Different therapeutic outcome in EAE using mouse IL-10 as protein or expressed by adenovirus or retrovirally transduced syngeneic fibroblasts. J.Immunol. 166: 4124-4130.
• Reichel MB , Bainbridge JWB, Baker D , Thrasher AJ, Bhattacharya SS and Ali RR. (2001) An immune response after intra-ocular administration of an adenoviral vector containing a beta galactosidase reporter gene slows retinal degeneration in the rd mouse. Br J Ophthalmol 85:341-344
• Hankey DRJ, Lightman SL and Baker D (2001) Interphotoreceptor retinoid binding protein peptide-induced uveitis in B10.RIII mice: characterisation of disease parameter and immunomodulation.. Exp Eye Res 72:341-50.
• Ahmed Z, Gveric D, Pryce G , Baker D , Leonard JP and Cuzner ML (2001) Myelin/axonal pathology in interleukin-12 induced serial relapses of experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol 2001, 158:2127-2138.
• Hankey DRJ, Nickerson JM, Donosa LA, Lightman SL and Baker D (2001) Experimental autoimmune uveoretinitis in mice (Biozzi ABH and NOD) expressing the autoimmune-associated H-2A g7 molecule:indentification of a uveitogenic epitope. J. Neuroimmunol 118:212-222.
• Morris-Downes M.M., McCormack K, Baker D , Sivaprasad D, Natkumarajah J and Amor S (2002) Encephalitogenic and immunogenic potential of myelin-associated glycoprotein (MAG), oligodendrocyte-specific glycoprotein (OSP) and 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) in ABH and SJL mice. J Neuroimmunol. 122:20-33.
• Walters CE, Pryce G, Hankey D, Baker D , Sebti SM, Greenwood J and Adamson P. (2002) Protein prenyl transferase inhibitors prevent lymphocyte recruitment to the CNS and prevent clinical signs of disease in an animal model of multiple sclerosis . J.Immunol . 168 4087-4094.
• Morris-Downes MM, Smith PA Rundle JL, Piddlesden SJ, Baker D , Pham-Dinh D, Heijmans N and Amor S. (2002) Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice. J Neuroimmunol. 125:114-124.
• Brooks JW, Pryce G, Bisogno T, Jagger S.I., Hankey DJR, Brown P, Bridges D, Ledent C.,Bifulco M, Rice AS, Di Marzo V and Baker D . (2002). Arvanil-induced inhibition of spasticity and persistent pain: Further evidence for additional therapeutic non-CB 1 cannabinoid receptors. Eur J Pharmacol. 439:83-92.
• Ahmed Z, Doward AI, Pryce G, Taylor D.L., Pocock JM, Leonard JP, Baker D and Cuzner ML (2002). A role for caspase 1 and -3 in the pathology of experimental allergic encephalomyelititis: inflammation verses degeneration. Am J Path. 161: 1577-1586.
• Thompson AJ and Baker D (2002) Cannabinoids in MS: Potentially useful but not just yet. Neurology. 58:1323-1323.
• Craner MJ, Lo AC Black JA, Baker D , Newcombe J, Cuzner ML and Waxman SG. (2003) Annexin II/p11 is upregulated in purkinje cells in EAE and MS. Neuroreport 14: 555-558
• Pryce G, Giovannoni G and Baker D . (2003) Mifepristone or inhibition of 11 b -hydroxylase activity potentiates the sedating effects of the CB1 agonist D (9)-tetrahydrocannabinol. Neurosci Letts,34:164-166.
• Greenwood J*, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D *, Adamson P* (2003) Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 2003;17:905-7. (* equal contribution )
• Petzold A, Baker D , Pryce C, Keir G, Thompson EJ and Giovannoni G. (2003) Quantitation of neurodegeneration by measurement of brain specific proteins. J .Neuroimmunol 138:45-8.
• Ahmed Z, Baker D , and Cuzner ML. (2003) IL-12 induces mild experimental allergic encephalomyelititis following local CNS injury. J Neuroimmunol 140:109-17.
• Pryce G, Ahmed Z, Hankey DRJ, Jackson S.L., Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner M.L. and Baker D (2003) Cannabinoids inhibit neurodegeneration in multiple sclerosis models. Brain.126 2191-202
• Hall R.J. Hollis-Moffat JE, Merriman ME, Bridges RJ, Green RA, Williams G, Baker D and Merriman TR. (2003) An autoimmune diabetes locus ( Idd21 ) on mouse chromosome 18 . Mammalian Genome. 14:335-339.
• Craner MJ, Kataoka Y, Lo AC, Black JA, Baker D , and Waxman SG (2003). Temporal course of upregulation of Na v 1.8 in Purkinje neurons parallels the progression of clinical deficit in EAE. J Neuropathol Exp Neurol. 2003; 62:968-75.
• Wilkinson JD, Whalley BJ, Baker D , Pryce G, Constanti A, Gibbons S, Williamson EM.(2003) Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects? J. Pharm Pharmacol.55:1687-1694 .
• Baker D , Adamson P and Greenwood J. (2003) Statins in multiple sclerosis. Lancet Neurol. 2: 9-10
• Baker D and Pryce G (2003) The therapeutic potential of cannabis in multiple sclerosis. Expert Opin on Invest Drugs 12:561-567.
• Baker D , Pryce G, Giovannoni G and Thompson A. (2003) The therapeutic potential of cannabis Lancet Neurol 2:291-298
• Baker D and Hankey DRJ (2003) Gene therapy of central nervous system autoimmune demyelinating disease of the central nervous system. Gene ther. 10:844-53.
• Giovannoni G and Baker D (2003 ) Inflammatory disorders of the central nervous system. Curr Opin Neurol 16:347-350
• Baker D and Pryce G (2004). The potential role of the endocannabinoid system in the control of multiple sclerosis. Curr Med Chem-CNS agents. 4: 195-202
• De Lago E, Ligresti A, de Lago E, Ortar G, Morera E, Cabranes A, Pryce G, Bifulco M, Baker D , Fernadez-Ruiz J and Di Marzo V . (2004 ) In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake Eur. J Pharmacol ;484:249-57.
• Ellmerich S, Takacs K, Waldner H, Mycko M, Wahid F, Boyton R , Smith PA, Amor S, Baker D , Hafler D, Kuchroo V and Altmann DM (2004). Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis. Eur. J. Immunol. 34:1839-48.
• Jackson SJ, Baker D, Cuzner ML, Diemel LT. (2004). Cannabinoid-mediated neuroprotection following interferon-gamma treatment in a three-dimensional mouse brain aggregate cell culture. Eur J Neurosci. 2004 20:2267-75
• Pryce G and Baker D (2004) Cannabinoids in medicine II: Multiple sclerosis and neuronal damage. In Cannabinoids Ed Di Marzio V. R.G. Landes Company. Austin . Pg 161-180.
• Baker D. (2004) Therapeutic potential of cannabis and cannabinoids in experimental models of multiple sclerosis. In The medical uses of cannabis and cannabinoids. Eds GW. Guy, BA. Whittle & PJ Robson. Pharmaceutical press. London pg 141-163. ISBN 0 85369 517 2
• Gegg ME, Harry R, Hankey D, Zambarakji H, Pryce G, Baker D , Adamson P, Calder V and Greenwood J. (2005) Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. J.Immunol. 174:2327-35.
• Visintin C, Aliev AE, Riddall D, Baker D, Okuyama M, Hoi PM, Hiley R, and Selwood DL (2005) Membrane receptor probes:solid phase synthesis of biotin-Asp-PEG-arvanil derivates. Organic Letts. 7:1699-702.
• Pryce G and Baker D. (2005) The emerging properties of Cannabinoid Medicines in the Management of Multiple Sclerosis. Trends Neurosci. 28:272-276.
• Jackson SL, Pryce G, Diemel DT and Baker D (2005) Cannabinoid receptor null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience. 134:261-8.
• Smith PA, Morris-Downes MM, Nicole Heijmans N, Pryce G, O'Neill JK, Baker D and Amor S. (2005). Epitope spread may Influence but is not necessary for the development of relapses in CNS autoimmune Disease. J. Neuroimmunol. 164:76-84.
• Jackson SJ, Diemel LT, Pryce G and Baker D. (2005). Cannabinoid receptor 1 and neuroprotection in CNS inflammatory Disease. J. Neurol Sci. 233:21-5.
• Idris A, van 't Hof RJ, Greig IR, Ridge SA, Baker D , Ross RA and Ralston SH (2005) Regulation of osteoclastic bone resorption in vitro and in vivo by cannabinoid receptor antagonism. Nat Med. 11:774-9.
• Pryce G, O'Neill JKA, Croxford JL, Amor S, Hankey DRJ, Giovannoni G and Baker D (2005). I mmunological tolerance that eliminates relapses, fails to halt secondary progression in a chronic multiple sclerosis model. J.Neuroimmunol. 165:41-52.
• East E, Baker D, Pryce G, Lijnen RH, Cuzner ML and Gveric D. (2005). A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelititis. Am. J. Path. 167:545-54.
• Heijmans N, Smith PA, Morris-Downes MM, Pryce G, Baker D, Donaldson AVJ, 't Hart B and Amor S. (2005) Inhibition of relapsing EAE with non-encephalitogenic APL of MOG and PLP in Biozzi ABH mice. J.Neuroimmunol 164:76-84 .
• Amor S, Smithh PA, t'Hart B and Baker D. (2005) Biozzi mice: Of mice and human neurological diseases. J. Neuroimmunol. 165:1-10.
• Baker D . (2005) Genetics of experimental allergic encephalomyelitis in. "Experimental Models of Multiple Sclerosis", E. Lavi and C Constantinescu (eds) Springer Science + Business Media, New York. Pg. 181-200. ISBN 0-387-25517-6
• Constantinescu CS and Baker D (2005) Cytokines in experimental autoimmune encephalomyelitis. In "Experimental Models of Multiple Sclerosis", E. Lavi and C Constantinescu (eds) Springer Science + Business Media, New York . Pg. 283-311. ISBN 0-387-25517-6
• Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I, De Petrocellis L, Saha B, Mahadevan A, Visintin C, Baker D, Wiley J, Martin BR, Razdan R.K. Di Marzo V. (2006). New potent and selective inhibitors of anandamide re-uptake with anti-spastic activity in a mouse model of multiple sclerosis. Brit. J. Pharm. 147:83-91.
• De Lago E, Fernández-Ruiz J, Ortega-Gutiérrez S, Cabranes A, Pryce G, Baker D, López-Rodríguez, and Ramos JA. (2006) UCM707, an inhibitor of anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. Eur Neuropsychopharmacol. 16:7-18.
• Baker D, Pryce G. Davies W.L. and Hilley CR (2006). In silico patent searching identifies a new cannabinoid receptor? Submitted for publication. Trends Pharm Sci. 27:1-4
• Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, and Di Marzo V. (2006) Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience. 139:1405-1415.
• Bilsland LG, Dick JRT, Pryce G, Petrosino S, Di Marzo V, Baker D and Greensmith L. (2006) Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J; 20:1003-5.
• Cabranes A, Pryce G, Baker D, and Fernández-Ruiz J. (2006) Changes in CB 1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Brain Research. 1107:199-205 .
• Pryce G and Baker D (2007). Control of Spasticity in a Multiple Sclerosis Model is CB 1, not CB 2, cannabinoid receptor mediated. Brit J Pharmacol. 150:519-525.
• Baker D, Jackson SJ, Pryce G (2007) Cannabinoid control of neuroinflammation. Brit J. Pharm. 152. 649-654
• Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng X, Carrier E, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN (2007). Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB 1 on neurons and CB 2 on autoreactive T Cells. Nat Medicine 13:492-497.
• Hoi PM, Visintin C, Okuyama M, Gardiner SM, Kaup SS, Bennett, Baker D, Selwood DL, CR Hiley (2007). Vascular pharmacology of a novel cannabinoid-like compound, 3 (5 dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat. Brit J. Pharm. 152: 751-764.
•
East E, Gveric D, Baker D, Pryce G, Lijnen RH and Cuzner ML. (2007) Reduction of disease severity in chronic EAE in PAI-1 knockout mice; the beneficial effect of removal of fibrin during neuroinflammation. Neuropathology and Applied Neurobiology. Nov 5; [Epub Nov 5].
• Baker D, Pryce G, Croxford JL and Yamamura T. (2007) Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitits. Curr Top Neuroimmunol. In press.
• Pryce G, Jackson SJ Baker D (2007). Cannabinoids for the control of multiple sclerosis. In cannabinoids and the brain. Köfalvi A (Ed), Springer, Norwell, Massachusetts, USA. In press.
• Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertweee RG, Yamamura T, Baker D. Cannabinoid-mediated neuroprotection, not immunosuppression, may be relevant to multiple sclerosis. J.Neuroimmunol. in press.
• Baker D and Jackson SJ (2007). Models of multiple sclerosis. Adv Clin Neurosci Rehab. In press.
• Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertweee RG, Yamamura T, Baker D. Balancing the effects of cannabinoid control in experimental models of multiple sclerosis: CB 1 immunosuppression verses neuroprotection. Submitted for publication.
• East E, Gveric D, Baker D, Pryce G, Lijnen RH and Cuzner ML. Reduction of disease severity in chronic EAE in PAI-1 knockout mice; the beneficial effect of removal of fibrin during neuroinflammation. Submitted for publication.
• Hampton DW, Anderson J, Pryce G, Franklin RJ, Giovannoni G, Fawcett J.W., Compston A, Blakemore WF, Baker D, Chandran S. An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination and neuronal loss. Submitted for publication.
• Pinteaux-Jones F, Sevastou I.G., Fry VAH, Heales S, Baker D and Pocock JM. Myelin-induced neurotoxicity can be controlled by microglial metabotropic glutamate receptors. Submitted for publication
• Hooper C, Pinteaux-Jones F, Fry VAH, Baker D, Heales SJ, Pocock JM. Differential effects of albumin on microglia and macrophages; implications for neurodegeneration following blood-brain barrier damage. Submitted for publication
• Anderson JM, Hampton DW, Pryce G, Crowther RA, Reynolds R, Franklin RJM, Giovannoni G, Compston DAS, Baker D, Spillantini MG, Chandran S. Abnormally phosphorylated tau is associated with neuronal and axonal loss in multiple sclerosis. Submitted for publication.